Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Journal of Hepatocellular Carcinoma · 2024-01 · Volume 11 · 29-38
DOI: 10.2147/jhc.s443779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2024-01. Verfasst von Liwei Deng und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Electronic Science and Technology of China, Chengdu, People's Republic of China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
To compare the efficacy and safety of transarterial chemoembolization (TACE) plus donafenib with immune checkpoint inhibitors (ICIs) (T+D+I) versus TACE plus donafenib (T+D) as the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC).
Methods
This retrospective study included patients with unresectable HCC who received T+D+I or T+D between June 2021 and February 2023. The tumor response was analyzed according to the modified Response Evaluation Criteria in Solid Tumors. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs) in the two groups were compared before and after propensity score matching (PSM). Cox's proportional-hazards regression model was used to analyze factors affecting PFS and OS.
Results
This study included 69 patients: 41 patients in the T+D group and 28 patients in the T+D+I group. After PSM, 26 patients in each group were analyzed. Patients in the T+D+I group had a higher DCR (96.2% vs 73.1%, P = 0.021), longer median PFS (13.1 vs 7.2 months, P = 0.017), and longer median OS (23.1 vs 14.7 months, P = 0.021) than those in the T+D group. The ORR in the two groups was similar (53.8% vs 50.0%, P = 0.781). Multivariate analyses revealed that T+D+I treatment and total bilirubin levels of 0.05).
Conclusion
In comparison with TACE plus donafenib, TACE plus donafenib with ICIs could significantly improve DCR, PFS, and OS as a potential first-line treatment for unresectable HCC with an acceptable safety profile.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, University of Electronic Science and Technology of China, Chengdu, People's Republic of China.
- Department of Interventional Therapy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu, People's Republic of China.
- Department of Hepato-Biliary-Pancreatic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu, People's Republic of China.
Zitieren
APA
Deng, L., Sun, Y., Wang, H., Liao, C., Li, D., Xu, G., & Yang, X. (2024). Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma, Volume 11, 29-38. https://doi.org/10.2147/jhc.s443779
Vancouver
Deng L, Sun Y, Wang H, Liao C, Li D, Xu G, et al. Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma. 2024;Volume 11:29-38. doi:10.2147/jhc.s443779
BibTeX
@article{Deng2024,
author = {Deng, Liwei and Sun, Yanyuan and Wang, Haiqing and Liao, Changli and Li, Deshan and Xu, Guohui and Yang, Xuegang},
title = {Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis},
journal = {Journal of Hepatocellular Carcinoma},
year = {2024},
volume = {Volume 11},
pages = {29--38},
doi = {10.2147/jhc.s443779}
}
EUVIMED